

Changing the NCI's Clinical Trials System to Meet the Needs of the 21st Century

James H. Doroshow, M.D.
Division of Cancer Treatment and Diagnosis
National Cancer Institute, NIH



National Cancer Advisory Board


Bethesda, MD
June 22, 2010

Changing the NCI's Clinical Trials System to Meet the Needs of the 21st Century

Report of the
Clinical Trials Working Group
of the
National Cancer Advisory Board

Restructuring the
National Cancer Clinical Trials
Enterprise

June 2005



Report of the Operational Efficiency
Working Group
of the
Clinical Trials and Translational
Research Advisory Committee

Compressing the Timeline for Cancer
Clinical Trial Activation

March 2010



Report of the Translational Research Working
Group of the National Cancer Advisory Board

**Transforming Translation—
Harnessing Discovery
for Patient and Public Benefit**

June 2007



U.S. DEPARTMENT
OF HEALTH AND
HUMAN SERVICES
National Institutes
of Health

Our clinical trials system must reflect the dramatic changes in cancer biology that occurred over the past 15-20 yrs.

What do we need to change?

- Improve the speed and efficiency of the development and conduct of trials
- Incorporate innovative science and trial design into our studies
- Improve prioritization, support, and completion of trials
- Incentivize the participation of patients and physicians in clinical investigations

What have we changed?

- Resources for the development of predictive biomarkers
- Clinical trial prioritization
- Operational efficiency standards for trial development
- Regulatory & administrative support
- Modernized clinical trial IT infrastructure

Where do we go from here?

NCI National Clinical Trials System

